The number of knee replacements doubled in 16 years, but did recipients’ lives improve as a result? With health expenditure set to outpace GDP growth, collecting data to answer questions like this is crucial
At a Science|Business event in Norway, students, technology experts and teachers debated the merits of new breeds of healthcare delivery. There are benefits, but digital health must be thoughtfully controlled and users properly trained
New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new Innovative Medicines Initiative Call for proposals.
Some medicines may carry a higher risk of side effects for the lungs than previously thought, IMI research reveals. The drugs studied work well for most, but doctors should monitor patients for side effects.
Spain is widely regarded as having one of the world’s best healthcare systems. Can a series of experiments in ‘value-based’ care help to make it even better? A new Science|Business report finds out
In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.
In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.
The eTOX project developed innovative strategies and novel software tools to better predict the safety and side effects of new candidate medicines for patients. In an interview, the project leaders explain how the tools developed by the project are already helping pharmaceutical companies make better-informed decisions in their pursuit of developing safer drugs for patients.
At the Euroscience Open Forum conference, a Bulgarian medical start-up demonstrates the potential - and the challenges - of getting health systems to focus on preventing disease, rather than responding when it strikes
Liquid biopsies can help to diagnose cancer in its early stages, and assist clinicians in monitoring the impact of treatment at any point. IMI's CANCER-ID project has validated a series of tests for cancer cells to help develop more effective methods of diagnosis and more personalised treatments for lung and breast cancer - two of the most frequent malignancies in Europe.
‘Radical collaboration’ where multinational companies work together and share data instead of keeping it secret is helping to change the model of the pharmaceutical industry and solve problems more quickly, according to Carlos Moedas, the EU’s commissioner for research, science and innovation, speaking at an IMI 10th anniversary event in Brussels on 27 June.
High consumption rates and the widespread use of broad-spectrum antibiotics is worrying, and ‘Romania is at a cross-roads’ says the European Centre for Disease Prevention and Control.
An app developed by Google’s AI company saves nurses two hours a day. But so far it is free to use. An independent panel says DeepMind must clarify the business model, a stark illustration that as healthcare AI goes mainstream, the matter of who does what with patient data is coming into sharper focus
It is crucial to incorporate patient perspectives on healthcare innovation and decision making to increase the sustainability of Europe’s healthcare systems. A panel held at the Science|Business annual conference looked at the role Horizon Europe can play in achieving this
Funding science and providing incentives to spur innovation in antibiotics is crucial, but political support for stewardship and prevention of inappropriate use is just as important in ensuring availability of effective and affordable drugs that are used in a responsible way
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.